Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1962 6
1963 2
1964 4
1965 3
1966 1
1967 2
1968 1
1969 5
1970 2
1971 9
1972 10
1973 5
1974 8
1975 5
1976 4
1977 5
1978 6
1979 6
1980 6
1981 14
1982 10
1983 14
1984 12
1985 16
1986 23
1987 19
1988 20
1989 15
1990 17
1991 12
1992 32
1993 20
1994 31
1995 23
1996 33
1997 36
1998 47
1999 37
2000 43
2001 42
2002 53
2003 46
2004 45
2005 36
2006 26
2007 27
2008 30
2009 40
2010 46
2011 48
2012 56
2013 55
2014 62
2015 59
2016 77
2017 93
2018 76
2019 83
2020 120
2021 141
2022 163
2023 130
2024 141

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,025 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for okada a
Search for Ouada A instead (1 results)
Adolescent Health Promotion Interventions Using Well-Care Visits and a Smartphone Cognitive Behavioral Therapy App: Randomized Controlled Trial.
Nagamitsu S, Kanie A, Sakashita K, Sakuta R, Okada A, Matsuura K, Ito M, Katayanagi A, Katayama T, Otani R, Kitajima T, Matsubara N, Inoue T, Tanaka C, Fujii C, Shigeyasu Y, Ishii R, Sakai S, Matsuoka M, Kakuma T, Yamashita Y, Horikoshi M. Nagamitsu S, et al. Among authors: okada a. JMIR Mhealth Uhealth. 2022 May 23;10(5):e34154. doi: 10.2196/34154. JMIR Mhealth Uhealth. 2022. PMID: 35604760 Free PMC article. Clinical Trial.
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Ohji M, et al. Among authors: okada aa. Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3. Adv Ther. 2020. PMID: 32016788 Free PMC article. Clinical Trial.
Behçet Uveitis.
Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M. Cunningham ET Jr, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2017 Feb;25(1):2-6. doi: 10.1080/09273948.2017.1279840. Ocul Immunol Inflamm. 2017. PMID: 28195819 No abstract available.
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, Matsumoto H, Mukai R, Nagai Y, Ohnaka M, Kusuhara S, Miki A, Okada AA, Nakayama M, Nishiguchi KM, Takeuchi J, Mori R, Tanaka K, Honda S, Kohno T, Koizumi H, Miyara Y, Inoue Y, Takana H, Iida T, Maruko I, Hayashi A, Ueda-Consolvo T, Yanagi Y. Inoda S, et al. Among authors: okada aa. Retina. 2024 Apr 1;44(4):714-722. doi: 10.1097/IAE.0000000000004009. Retina. 2024. PMID: 38016089
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. Suzuki Y, et al. Among authors: okada a. Cardiovasc Diabetol. 2022 May 18;21(1):67. doi: 10.1186/s12933-022-01508-6. Cardiovasc Diabetol. 2022. PMID: 35585590 Free PMC article.
COVID Vaccine-Associated Uveitis.
Habot-Wilner Z, Neri P, Okada AA, Agrawal R, Xin Le N, Cohen S, Fischer N, Kilmartin F, Coman A, Kilmartin D. Habot-Wilner Z, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2023 Aug;31(6):1198-1205. doi: 10.1080/09273948.2023.2200858. Epub 2023 May 5. Ocul Immunol Inflamm. 2023. PMID: 37145198 Review.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Kataoka K, et al. Among authors: okada aa. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37668741
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators. Mori R, et al. Among authors: okada aa. Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11. Jpn J Ophthalmol. 2023. PMID: 37039948 Free PMC article. Clinical Trial.
2,025 results